Illumina Inc. (ILMN): Price and Financial Metrics
ILMN Price/Volume Stats
| Current price | $117.48 | 52-week high | $229.58 |
| Prev. close | $116.69 | 52-week low | $89.00 |
| Day low | $117.00 | Volume | 690,239 |
| Day high | $119.22 | Avg. volume | 1,749,390 |
| 50-day MA | $133.38 | Dividend yield | N/A |
| 200-day MA | $140.18 | Market Cap | 18.71B |
ILMN Stock Price Chart Interactive Chart >
Illumina Inc. (ILMN) Company Bio
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California. (Source:Wikipedia)
Latest ILMN News From Around the Web
Below are the latest news stories about ILLUMINA INC that investors may wish to consider to help them evaluate ILMN as an investment opportunity.
Here's Why You Should Retain Illumina (ILMN) Stock for NowInvestors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position. |
Small Caps Are On A Tear Including Speculative BiotechsSo far 2023 is going well with our game plan -an end-of-year seasonal rally coupled with a run in speculative biotechs driven by innovation. |
Nucleus Genomics Wants To Make Personalized Health Care a RealityNORTHAMPTON, MA / ACCESSWIRE / December 21, 2023 / Illumina A New York-based startup is on a mission to bring the power of whole-genome sequencing to the world Originally published on Illumina News Center Nucleus Genomics is realizing the dream set ... |
Heard on the Street: Illumina Nears the End of Its Painful Grail SagaGrail’s screening test, called Galleri, could one day help save countless lives by catching cancer in the bloodstream early. After losing in court [against the Federal Trade Commission](https://www.wsj.com/health/healthcare/court-sides-with-ftc-finding-illumina-grail-deal-anticompetitive-ad2efe8d), the company has finally [thrown in the towel](https://www.wsj.com/health/healthcare/illumina-to-divest-itself-of-cancer-test-maker-grail-3f74f1e8) on keeping Grail. The maker of gene-sequencing machines said Sunday it will pursue the divestiture of Grail through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of 2024. |
S&P 500 Gains and Losses Today: Enphase's Cost Cutting Charges Up Solar StocksThe S&P 500 gained 0.6% on Tuesday, Dec. 19, 2023, amid optimism on Fed rate cuts, strong housing data, and the traditional "Santa Claus rally." |
ILMN Price Returns
| 1-mo | -11.80% |
| 3-mo | -13.54% |
| 6-mo | -1.81% |
| 1-year | -47.91% |
| 3-year | -70.51% |
| 5-year | -63.18% |
| YTD | -15.63% |
| 2023 | -31.14% |
| 2022 | -46.85% |
| 2021 | 2.82% |
| 2020 | 11.53% |
| 2019 | 10.61% |
Continue Researching ILMN
Want to do more research on Illumina Inc's stock and its price? Try the links below:Illumina Inc (ILMN) Stock Price | Nasdaq
Illumina Inc (ILMN) Stock Quote, History and News - Yahoo Finance
Illumina Inc (ILMN) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...